SCHEMBL4707809

SCHEMBL4707809

O=Cc1cnn2c(-c3ccccc3)c(-c3ccc(OCc4ccccc4)cc3)cnc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSTP1 P09211 2/20 0.45
GRM2 Q14416 1/20 0.40
CSNK2A2 P19784 1/20 0.39
CSNK2B P67870 1/20 0.39
CSNK2A1 P68400 1/20 0.39
ERN1 O75460 1/20 0.39
MAPT P10636 3/20 0.38
NPSR1 Q6W5P4 3/20 0.38
DGAT1 O75907 1/20 0.38
MAOB P27338 3/20 0.38
BACE1 P56817 2/20 0.37
KDM4E B2RXH2 1/20 0.37
HSP90AA1 P07900 1/20 0.37
MAPK1 P28482 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
PIK3CD O00329 1/20 0.37
PIK3CA P42336 1/20 0.37
PIK3CB P42338 1/20 0.37
PIK3CG P48736 1/20 0.37
PRKDC P78527 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14014406 0.83 MCL1 (0.48) GSTP1MAPTMAOBKDM4E
SCHEMBL14014486 0.83 MCL1 (0.48) GSTP1MAPTMAOBKDM4E
SCHEMBL4707693 0.83 GSTP1 (0.45) GSTP1GRM2MAPTNPSR1MAOB
SCHEMBL4709616 0.83 PTGES (0.47) GSTP1GRM2MAPTNPSR1MAPK1
SCHEMBL4708684 0.82 GSTP1 (0.44) GSTP1GRM2MAPTNPSR1DGAT1
SCHEMBL4707806 0.82 ALOX5 (0.42) GSTP1GRM2CSNK2A2CSNK2BCSNK2A1
SCHEMBL14014391 0.80 GRM2 (0.48) GSTP1GRM2MAPTMAOBKDM4E
SCHEMBL4709978 0.80 GRM2 (0.48) GSTP1GRM2MAPTMAOBKDM4E
SCHEMBL14014445 0.79 NPC1 (0.56) MAPTDGAT1KDM4EHSP90AA1TDP1
SCHEMBL14014390 0.79 NPC1 (0.56) MAPTDGAT1KDM4EHSP90AA1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7449488-B2 Pyrazolopyrimidines as protein kinase inhibitors SCHERING CORPORATION (US) 2008-11-11 US disclosed
EP-1511751-B1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS NEOGENESIS PHARMACEUTICALS INC (US) 2008-03-19 EP disclosed
US-7196111-B2 Pyrazolo[1,5a]pyrimidine compounds as antiviral agents SCHERING CORPORATION (US) 2007-03-27 US disclosed
US-20060094706-A1 Pyrazolopyrimidines as protein kinase inhibitors SCHERING CORPORATION 2006-05-04 US disclosed
US-20040038993-A1 Pyrazolo[1,5a]pyrimidine compounds as antiviral agents NEOGENESIS PHARMACEUTICALS, INC. 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038993-A1 Pyrazolo[1,5a]pyrimidine compounds as antiviral agents RNGTT, PNP, ZC3HAV1 GSTP1 579/4885GRM2 4799/4885CSNK2A2 3672/4885
US-20060094706-A1 Pyrazolopyrimidines as protein kinase inhibitors CDKN1A, EIF2AK2, DCK GSTP1 1366/4885GRM2 4195/4885CSNK2A2 468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.